

Scott A North

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9301416/publications.pdf>

Version: 2024-02-01

117
papers

12,966
citations

76196

40
h-index

24915

109
g-index

117
all docs

117
docs citations

117
times ranked

12028
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Abiraterone and Increased Survival in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2011, 364, 1995-2005. | 13.9 | 3,736 |
| 2 | Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor-Targeted Agents: Results From a Large, Multicenter Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 5794-5799. | 0.8 | 1,751 |
| 3 | Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. <i>Lancet Oncology</i> , The, 2012, 13, 983-992. | 5.1 | 1,182 |
| 4 | Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 121-131. | 13.9 | 982 |
| 5 | Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy. <i>European Urology</i> , 2017, 72, 544-554. | 0.9 | 638 |
| 6 | The Impact of Cytoreductive Nephrectomy on Survival of Patients With Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor Targeted Therapy. <i>Journal of Urology</i> , 2011, 185, 60-66. | 0.2 | 322 |
| 7 | A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. <i>Cancer</i> , 2007, 110, 1959-1966. | 2.0 | 276 |
| 8 | Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. <i>Lancet Oncology</i> , The, 2012, 13, 1210-1217. | 5.1 | 254 |
| 9 | Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2015, 67, 241-249. | 0.9 | 235 |
| 10 | Randomized Phase II Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 4247-4254. | 0.8 | 221 |
| 11 | Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302). <i>European Urology</i> , 2014, 66, 815-825. | 0.9 | 221 |
| 12 | Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria. <i>Cancer</i> , 2013, 119, 2999-3006. | 2.0 | 189 |
| 13 | Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 6487-6497. | 3.2 | 121 |
| 14 | Randomized Phase II Trial of Custirsen (OGX-011) in Combination with Docetaxel or Mitoxantrone as Second-line Therapy in Patients with Metastatic Castrate-Resistant Prostate Cancer Progressing after First-line Docetaxel: CUOG Trial P-06c. <i>Clinical Cancer Research</i> , 2011, 17, 5765-5773. | 3.2 | 120 |
| 15 | Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. <i>Lancet Oncology</i> , The, 2012, 13, 927-935. | 5.1 | 112 |
| 16 | Associations between Exercise and Quality of Life in Bladder Cancer Survivors: A Population-Based Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 984-990. | 1.1 | 86 |
| 17 | The 2014 CUA-CUOG Guidelines for the Management of Castration Resistant Prostate Cancer (CRPC). <i>Canadian Urological Association Journal</i> , 2015, 9, 90. | 0.3 | 82 |
| 18 | Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancer. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 1406-1414. | 1.0 | 78 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Outcome of Patients With Metastatic Sarcomatoid Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e79-e85. | 0.9 | 78 |
| 20 | Vaccination with BLP25 liposome vaccine to treat non-small cell lung and prostate cancers. <i>Expert Review of Vaccines</i> , 2005, 4, 249-257. | 2.0 | 76 |
| 21 | Exercise programming and counseling preferences in bladder cancer survivors: a population-based study. <i>Journal of Cancer Survivorship</i> , 2007, 1, 27-34. | 1.5 | 75 |
| 22 | Clinical Outcome in Metastatic Renal Cell Carcinoma Patients After Failure of Initial Vascular Endothelial Growth Factor-Targeted Therapy. <i>Urology</i> , 2010, 76, 430-434. | 0.5 | 75 |
| 23 | Effects of high-intensity aerobic interval training on cardiovascular disease risk in testicular cancer survivors: A phase 2 randomized controlled trial. <i>Cancer</i> , 2017, 123, 4057-4065. | 2.0 | 74 |
| 24 | Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 3181-3188. | 0.8 | 73 |
| 25 | Survival Outcome and Treatment Response of Patients with Late Relapse from Renal Cell Carcinoma in the Era of Targeted Therapy. <i>European Urology</i> , 2014, 65, 1086-1092. | 0.9 | 71 |
| 26 | Effects of high-intensity interval training on fatigue and quality of life in testicular cancer survivors. <i>British Journal of Cancer</i> , 2018, 118, 1313-1321. | 2.9 | 70 |
| 27 | The Impact of Low Serum Sodium on Treatment Outcome of Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Cancer Database Consortium. <i>European Urology</i> , 2014, 65, 723-730. | 0.9 | 69 |
| 28 | Stereotactic Radiotherapy for Oligoprogression in Metastatic Renal Cell Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Phase 2 Prospective Multicenter Study. <i>European Urology</i> , 2021, 80, 693-700. | 0.9 | 65 |
| 29 | Prognostic Factors of Survival for Patients With Metastatic Renal Cell Carcinoma With Brain Metastases Treated With Targeted Therapy: Results From the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 311-315. | 0.9 | 64 |
| 30 | Defining cisplatin eligibility in patients with muscle-invasive bladder cancer. <i>Nature Reviews Urology</i> , 2021, 18, 104-114. | 1.9 | 57 |
| 31 | A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer†. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2005, 23, 143-149. | 0.8 | 55 |
| 32 | Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015. <i>Canadian Urological Association Journal</i> , 2016, 10, 46. | 0.3 | 55 |
| 33 | Correlates of physical activity in a population-based sample of kidney cancer survivors: an application of the theory of planned behavior. <i>International Journal of Behavioral Nutrition and Physical Activity</i> , 2012, 9, 96. | 2.0 | 52 |
| 34 | A prospective study of the determinants of exercise in bladder cancer survivors using the Theory of Planned Behavior. <i>Supportive Care in Cancer</i> , 2009, 17, 171-179. | 1.0 | 50 |
| 35 | Impact of Bone-targeted Therapies in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer Patients Treated with Abiraterone Acetate: Post Hoc Analysis of Study COU-AA-302. <i>European Urology</i> , 2015, 68, 570-577. | 0.9 | 50 |
| 36 | A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naïve castration resistant prostate cancer. <i>Investigational New Drugs</i> , 2012, 30, 1652-1659. | 1.2 | 47 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients. <i>Targeted Oncology</i> , 2013, 8, 203-209. | 1.7 | 47 |
| 38 | Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer. <i>European Urology</i> , 2020, 78, 834-844. | 0.9 | 47 |
| 39 | Associations Between Physical Activity and Quality of Life in a Population-Based Sample of Kidney Cancer Survivors. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 859-868. | 1.1 | 41 |
| 40 | Management of small cell carcinoma of the bladder: Consensus guidelines from the Canadian Association of Genitourinary Medical Oncologists (CAGMO). <i>Canadian Urological Association Journal</i> , 2013, 7, 44. | 0.3 | 41 |
| 41 | A population-based study examining the effect of tyrosine kinase inhibitors on survival in metastatic renal cell carcinoma in Alberta and the role of nephrectomy prior to treatment. <i>Canadian Urological Association Journal</i> , 2013, 3, 281. | 0.3 | 39 |
| 42 | Physical activity preferences in a population-based sample of kidney cancer survivors. <i>Supportive Care in Cancer</i> , 2012, 20, 1709-1717. | 1.0 | 37 |
| 43 | Randomized Controlled Trial of a Behavior Change Intervention to Increase Physical Activity and Quality of Life in Prostate Cancer Survivors. <i>Annals of Behavioral Medicine</i> , 2013, 46, 382-393. | 1.7 | 34 |
| 44 | Prostate-specific antigen doubling time is associated with survival in men with hormone-refractory prostate cancer. <i>Urology</i> , 2006, 68, 565-569. | 0.5 | 33 |
| 45 | First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience. <i>Canadian Urological Association Journal</i> , 2017, 11, 112. | 0.3 | 32 |
| 46 | Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>European Urology Oncology</i> , 2019, 2, 643-648. | 2.6 | 31 |
| 47 | L-BLP25: a MUC1-targeted peptide vaccine therapy in prostate cancer. <i>Expert Opinion on Biological Therapy</i> , 2007, 7, 1723-1730. | 1.4 | 30 |
| 48 | Quality indicators in the management of bladder cancer: A modified Delphi study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 328-334. | 0.8 | 29 |
| 49 | A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 201-208.e1. | 0.9 | 29 |
| 50 | The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 3.e17-3.e27. | 0.8 | 29 |
| 51 | Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP) Tj ETQq1 1 0.784314 rgBT /Over 837-846. | 0.8 | 29 |
| 52 | Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC).. <i>Journal of Clinical Oncology</i> , 2022, 40, LBA5004-LBA5004. | 0.8 | 29 |
| 53 | Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy. <i>European Urology</i> , 2021, 80, 275-279. | 0.9 | 28 |
| 54 | Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Cancer</i> , 2016, 122, 411-419. | 2.0 | 27 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Efficacy of Targeted Therapy for Metastatic Renal Cell Carcinoma in the Elderly Patient Population. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 354-358. | 0.9 | 26 |
| 56 | Management of urachal cancer: A review by the Canadian Urological Association and Genitourinary Medical Oncologists of Canada. <i>Canadian Urological Association Journal</i> , 2019, 14, E57-E64. | 0.3 | 26 |
| 57 | Matrix metalloproteinase-2 contributes to increased platelet reactivity in patients with metastatic prostate cancer: a preliminary study. <i>Thrombosis Research</i> , 2003, 112, 59-64. | 0.8 | 25 |
| 58 | A Population-Based Overview of Sequences of Targeted Therapy in Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014, 12, e127-e131. | 0.9 | 25 |
| 59 | The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial. <i>European Journal of Cancer</i> , 2019, 108, 69-77. | 1.3 | 25 |
| 60 | 2019 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guidelines for the management of castration-resistant prostate cancer (CRPC). <i>Canadian Urological Association Journal</i> , 2019, 13, 307-314. | 0.3 | 21 |
| 61 | Social-ecological correlates of physical activity in kidney cancer survivors. <i>Journal of Cancer Survivorship</i> , 2016, 10, 164-175. | 1.5 | 20 |
| 62 | A rapid PSA half-life following docetaxel chemotherapy is associated with improved survival in hormone refractory prostate cancer. <i>Canadian Urological Association Journal</i> , 2013, 3, 369. | 0.3 | 19 |
| 63 | The Prognostic Role of the Change in Neutrophil-to-Lymphocyte Ratio During Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer: A Retrospective, Multi-Institutional Study. <i>Bladder Cancer</i> , 2018, 4, 185-194. | 0.2 | 19 |
| 64 | Neoadjuvant chemotherapy (NC) should be administered to fit patients with newly diagnosed, potentially resectable muscle-invasive urothelial cancer (MIUC) of the bladder – A 2013 CAGMO Consensus Statement and Call for a Streamlined Referral Process. <i>Canadian Urological Association Journal</i> , 2013, 7, 312. | 0.3 | 18 |
| 65 | Management of advanced kidney cancer: Canadian Kidney Cancer Forum consensus update. <i>Canadian Urological Association Journal</i> , 2015, 9, 164. | 0.3 | 18 |
| 66 | A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209. <i>Oncotarget</i> , 2018, 9, 8155-8164. | 0.8 | 18 |
| 67 | A Randomized, Phase III, Double-Blind, Placebo-Controlled Trial of Intrapleural Instillation of Methylprednisolone Acetate in the Management of Malignant Pleural Effusion. <i>Chest</i> , 2003, 123, 822-827. | 0.4 | 15 |
| 68 | CUA-CUOG Guidelines for the Management of Castration Resistant Prostate Cancer (CRPC): 2013 Update. <i>Canadian Urological Association Journal</i> , 2013, 7, 231. | 0.3 | 15 |
| 69 | Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 639.e1-639.e9. | 0.8 | 15 |
| 70 | Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 403-410.e2. | 0.9 | 14 |
| 71 | Associations between sitting time and quality of life in a population-based sample of kidney cancer survivors. <i>Mental Health and Physical Activity</i> , 2013, 6, 16-23. | 0.9 | 13 |
| 72 | Feasibility and Preliminary Efficacy of Adding Behavioral Counseling to Supervised Physical Activity in Kidney Cancer Survivors. <i>Cancer Nursing</i> , 2014, 37, E8-E22. | 0.7 | 13 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | The Canadian Urology Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone refractory prostate cancer progressing after mitoxantrone/prednisone. <i>BJU International</i> , 2008, 102, 551-555. | 1.3 | 12 |
| 74 | Treatment of muscle-invasive bladder cancer in Canada: A survey of genitourinary medical oncologists and urologists. <i>Canadian Urological Association Journal</i> , 2014, 8, 309. | 0.3 | 12 |
| 75 | Cisplatin- Versus Non-Cisplatin-based First-Line Chemotherapy for Advanced Urothelial Carcinoma Previously Treated With Perioperative Cisplatin. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 331-340. | 0.9 | 12 |
| 76 | Intermittent LHRH Therapy in the Management of Castrate-resistant Prostate Cancer (CRPCa). <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2013, 36, 601-605. | 0.6 | 11 |
| 77 | Improving the outcome of patients with muscle invasive urothelial carcinoma of the bladder with neoadjuvant gemcitabine/cisplatin chemotherapy: A single institution experience. <i>Canadian Urological Association Journal</i> , 2014, 8, 287. | 0.3 | 11 |
| 78 | Management of advanced kidney cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2021. <i>Canadian Urological Association Journal</i> , 2020, 15, 84-97. | 0.3 | 11 |
| 79 | Characteristics of Long-Term and Short-Term Survivors of Metastatic Renal Cell Carcinoma Treated With Targeted Therapies: Results From the International mRCC Database Consortium. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 150-155. | 0.9 | 10 |
| 80 | Management of Advanced Kidney Cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2019. <i>Canadian Urological Association Journal</i> , 2019, 13, 343-54. | 0.3 | 10 |
| 81 | Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma. <i>BJU International</i> , 2021, 127, 528-537. | 1.3 | 10 |
| 82 | 2021 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC) (full-text). <i>Canadian Urological Association Journal</i> , 2020, 15, E81-9. | 0.3 | 10 |
| 83 | First-Line Mammalian Target of Rapamycin Inhibition in Metastatic Renal Cell Carcinoma: An Analysis of Practice Patterns From the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 335-340. | 0.9 | 9 |
| 84 | Improving patient journey and quality of care: Summary from the second Bladder Cancer Canada-Canadian Urological Association- Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting. <i>Canadian Urological Association Journal</i> , 2018, 12, E281-97. | 0.3 | 9 |
| 85 | Outcome of advanced stage low grade follicular lymphomas in a population-based retrospective cohort. , 1999, 85, 1361-1368. | | 8 |
| 86 | Screen Failure Rates in Contemporary Randomized Clinical Phase II/III Therapeutic Trials in Genitourinary Malignancies. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e233-e242. | 0.9 | 8 |
| 87 | Canadian Urological Association/Genitourinary Medical Oncologists of Canada consensus statement: Management of unresectable locally advanced and metastatic urothelial carcinoma. <i>Canadian Urological Association Journal</i> , 2019, 13, 318-327. | 0.3 | 8 |
| 88 | Optimizing management of advanced urothelial carcinoma: A review of emerging therapies and biomarker-driven patient selection. <i>Canadian Urological Association Journal</i> , 2020, 14, E373-E382. | 0.3 | 8 |
| 89 | The Rapidly Evolving Landscape of First-Line Targeted Therapy in Metastatic Urothelial Cancer: A Systematic Review. <i>Oncologist</i> , 2021, 26, e1381-e1394. | 1.9 | 8 |
| 90 | Management of Advanced Kidney Cancer – Canadian Kidney Cancer Forum Consensus Update. <i>Canadian Urological Association Journal</i> , 2013, 7, 238. | 0.3 | 7 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | A multicentre analysis of abiraterone acetate in Canadian patients with metastatic castration resistant prostate cancer. <i>Canadian Urological Association Journal</i> , 2014, 8, 583. | 0.3 | 7 |
| 92 | Why consider neoadjuvant chemotherapy for muscle-invasive transitional cell carcinoma of the bladder?. <i>Canadian Urological Association Journal</i> , 2013, 2, 222. | 0.3 | 6 |
| 93 | Expression of Nucleoside Transporters and Deoxycytidine Kinase Proteins in Muscle Invasive Urothelial Carcinoma of the Bladder: Correlation with Pathological Response to Neoadjuvant Platinum/Gemcitabine Combination Chemotherapy. <i>Journal of Urology</i> , 2014, 191, 35-39. | 0.2 | 6 |
| 94 | Management of advanced kidney cancer: Canadian Kidney Cancer Forum (CKCF) consensus update 2017. <i>Canadian Urological Association Journal</i> , 2017, 11, 310-320. | 0.3 | 6 |
| 95 | Real-world Outcomes in Advanced Urothelial Cancer and the Role of Neutrophil to Lymphocyte Ratio. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e637-e644. | 0.9 | 6 |
| 96 | The role of the built environment in a randomized controlled trial to increase physical activity among men with prostate cancer: the PROMOTE trial. <i>Supportive Care in Cancer</i> , 2017, 25, 2993-2996. | 1.0 | 5 |
| 97 | Changes in motivational outcomes following a supervised physical activity program with behavioral counseling in kidney cancer survivors: a pilot study. <i>Psycho-Oncology</i> , 2015, 24, 1204-1207. | 1.0 | 4 |
| 98 | Sunitinib maintenance therapy after response to docetaxel in metastatic castration resistant prostate cancer (mCRPC). <i>Investigational New Drugs</i> , 2016, 34, 771-776. | 1.2 | 4 |
| 99 | Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer. <i>World Journal of Urology</i> , 2021, 39, 4345-4354. | 1.2 | 4 |
| 100 | A phase II trial of weekly i.v. KW-2170 in advanced castrate-resistant prostate cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2010, 6, 292-297. | 0.7 | 3 |
| 101 | Real world evidence: Abiraterone use post-docetaxel in metastatic castrate-resistant prostate cancer. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 1293-1300. | 0.5 | 3 |
| 102 | Continuing towards optimization of bladder cancer care in Canada: Summary of the 3rd BCC-CUA-CUOG bladder cancer quality of care consensus meeting. <i>Canadian Urological Association Journal</i> , 2019, 14, E115-E125. | 0.3 | 3 |
| 103 | Eligibility Criteria and Endpoints in Metastatic Renal Cell Carcinoma Trials. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 559-566. | 0.6 | 3 |
| 104 | Patterns of cost-related medication underuse among Canadian adults with cancer: a cross-sectional study using survey data. <i>CMAJ Open</i> , 2021, 9, E474-E481. | 1.1 | 3 |
| 105 | Small cell carcinoma of the genitourinary tract: A 10-year single institution experience.. <i>Journal of Clinical Oncology</i> , 2012, 30, 312-312. | 0.8 | 2 |
| 106 | Cost-effectiveness of enzalutamide versus apalutamide versus androgen deprivation therapy alone for the treatment of metastatic castration-sensitive prostate cancer in Canada. <i>Journal of Medical Economics</i> , 2022, 25, 583-590. | 1.0 | 2 |
| 107 | The prognostic impact of bone metastasis in patients with metastatic urothelial carcinoma treated with first-line platinum-based chemotherapy. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210948. | 1.4 | 2 |
| 108 | Perioperative chemotherapy for muscle invasive bladder cancer. <i>Current Opinion in Supportive and Palliative Care</i> , 2015, 9, 249-254. | 0.5 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | High fat mass associates with occurrence of targeted therapy-induced left ventricular ejection fraction reduction in patients with renal cell carcinoma. <i>Clinical Nutrition</i> , 2018, 37, 1070-1072. | 2.3 | 1 |
| 110 | Current Management of Localized Muscle-Invasive Bladder Cancer: A Consensus Guideline from the Genitourinary Medical Oncologists of Canada. <i>Bladder Cancer</i> , 2020, 6, 363-392. | 0.2 | 1 |
| 111 | Vascular endothelial growth factor (VEGF) therapy in metastatic renal cell carcinoma (mRCC): Differences between Asian and non-Asian patients.. <i>Journal of Clinical Oncology</i> , 2012, 30, 451-451. | 0.8 | 1 |
| 112 | Prise en charge du cancer du rein de stade avancé : Mise à jour 2013 des lignes directrices consensuelles du Forum canadien sur le cancer du rein. <i>Canadian Urological Association Journal</i> , 2013, 7, . | 0.3 | 0 |
| 113 | Development and Implementation of a Continuing Medical Education Program in Canada: Knowledge Translation for Renal Cell Carcinoma (KT4RCC). <i>Journal of Cancer Education</i> , 2019, 34, 14-18. | 0.6 | 0 |
| 114 | The management of malignant pleural effusions in breast cancer. , 2005, , 129-140. | | 0 |
| 115 | Assessing the utility of cabazitaxel in mCRPC. <i>Canadian Urological Association Journal</i> , 2016, 10, 111. | 0.3 | 0 |
| 116 | Socioeconomic disparities in the prevalence of comorbid chronic conditions among Canadian adults with cancer. <i>Acta Oncologica</i> , 2022, 61, 294-301. | 0.8 | 0 |
| 117 | Dr. North's rebuttal. <i>Canadian Urological Association Journal</i> , 2008, 2, 228. | 0.3 | 0 |